{"nctId":"NCT00446147","briefTitle":"Study of Pyridoxine for Hand-Foot Syndrome","startDateStruct":{"date":"2004-06"},"conditions":["Hand-foot Syndrome"],"count":389,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Pyridoxine","type":"EXPERIMENTAL","interventionNames":["Drug: Pyridoxine"]}],"interventions":[{"name":"Pyridoxine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Gastrointestinal tract cancer patients treated with capecitabine-containing chemotherapy as a first-line treatment were randomly allocated to concurrent treatment with pyridoxine or placebo.\n* All patients were 18 to 70 years old\n* Had Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower\n* An estimated life expectancy \\> 3 months\n* Adequate bone marrow function, including white blood cell (WBC) count of \\>3500 cells/㎕ and platelet count of \\>100000/㎕\n* Adequate renal function (serum creatinine concentration \\<1.5 mg/㎗)\n* Adequate liver function with (serum bilirubin concentration \\<1.5 mg/㎗, transaminase \\<3 times the upper normal limit, and serum albumin \\>2.5 mg/㎗).\n\nExclusion Criteria:\n\n* Previous treatment for HFS\n* Hypersensitivity to pyridoxine\n* A combination of other malignancies\n* Serious illnesses or medical conditions\n* Immune suppression or positive human immunodeficiency virus (HIV) serology\n* Pregnant or lactating women.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome","description":"A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70000","spread":null},{"groupId":"OG001","value":"70000","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Hand-foot Syndrome","description":"Number of patients with any grade of hand-foot syndrome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":180},"commonTop":[]}}}